Sentien Biotechnologies, Inc. is a clinical stage company developing novel approaches to cell therapy. The firm's lead product combines mesenchymal stromal cells (MSCs) within an approved blood-filtration device, allowing for controlled, sustained delivery of MSC secreted factors. Product being tested to treat systemic inflammatory diseases where MSCs can condition blood continuously during an acute illness.. Sentiens mission is to harness power of cell therapy with innovative drug delivery systems to treat a wide range of acute inflammatory diseases. The firm's lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors - an approach that immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection. in the fall 2016, Boehringer Ingelheim named Sentien its first LabCentral Golden Ticket winner. The Golden Ticket program enables high-level sponsors to underwrite the cost of a lab bench for a scientist to reside in the innovative, shared laboratory space for one year.
